Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Dual-receptor action By targeting both GIP and GLP-1 receptors, Tirzepatide signals fullness more completely than a single-agonist approach, reducing both hunger and caloric intake
Breaking through a weight loss plateau requires more than just diet and exercise
Human dosing does not translate cleanly to animals, and the right decision depends on species, size, diagnosis, and overall health
The most common adverse reactions (2% or greater) reported during the study were application site irritation (4.8%), application site erythema (3.7%), application site pruritus (3.7%), intercycle bleeding (3.9%), heavy withdrawal bleeding (2.0%), and nausea (2.0%)
